This work further details how the pharmacological blockade of CCK2R signaling alters the tumor microenvironment and demonstrates the effect of proglumide treatment on perfusion using the delivery of a nano-encapsulated imaging agent. The gene discussed is CCKBR; the disease is neoplasm.